Study Shows Infusion of Amino Acids Reduces Risk of Acute Kidney Injury Following Cardiac Surgery
Mild or moderate acute kidney injury has been linked to increased morbidity and mortality, with a greater risk of chronic kidney disease in patients who undergo cardiac surgery with cardiopulmonary bypass.
Image credit: Crystal light | stock.adobe.com
Findings from a Phase III trial (NCT03709264) show that intravenous (IV) infusion of amino acids in adults undergoing cardiac surgery lowers the risk of acute kidney injury (AKI).1,2 The authors of the study, published by The New England Journal of Medicine, noted that amino acids have been found to increase kidney perfusion and enlist renal functional reserve, but their efficacy in decreasing the occurrence of AKI following cardiac surgery remains unclear.
“Even mild or moderate AKI is independently associated with increased morbidity and mortality, including an increased risk of chronic kidney disease,” the study authors wrote. “In patients with severe AKI, kidney-replacement therapy is common and is associated with doubling of hospitalization costs, decreased quality of life, and higher long-term mortality. However, other than the implementation of supportive measures, there is no single preventive intervention for cardiac surgery–associated AKI.”1
The authors added that prior research indicates infusing amino acids elevates nephron plasma flow by reducing afferent arteriolar resistance, lowering tubuloglomerular feedback activation, and increasing cortical nitric oxide synthase activity.
“Moreover, in studies in animals, amino acid infusion increased renal perfusion, renal oxygenation, and GFR,” the study authors wrote. “Finally, pilot studies in humans have shown evidence that amino acid infusion is safe and has beneficial short-term and long-term effects on kidney function after cardiac surgery, as well as potential survival benefits in critical illness in general.”1
The multinational, double-blind, randomized trial enrolled adults scheduled to undergo cardiac surgery with cardiopulmonary bypass. Patients received IV infusion of a balanced mix of amino acids (2 g per kilogram of ideal body weight per day) or a placebo for up to three days. The trial’s primary outcome was occurrence of AKI as defined by Kidney Disease: Improving Global Outcomes creatinine criteria, with secondary outcomes that included severity of AKI, use and duration of kidney-replacement therapy, and all-cause 30-day mortality.
Inclusion criteria included being 18 years of age and older with a scheduled elective cardiac surgery requiring cardiopulmonary bypass, and patients were expected to stay in the intensive care unit for at least one night following the procedure. Patients were also required to have a baseline serum creatinine measurement prior to the procedure.
A total of 3511 patients were included from 22 centers in three countries. Investigators randomly assigned 1759 patients to the amino acid cohort and 1752 patients to the placebo cohort. AKI was observed in 474 patients (26.9%) in the amino acid cohort compared to 555 (31.7%) patients in the placebo cohort (relative risk, 0.85; 95% confidence interval [CI], 0.77 to 0.94; P=0.002).
Stage 3 AKI was observed in 29 patients (1.6%) in the amino acid cohort compared to 52 patients (3.0%) in the placebo cohort (relative risk, 0.56; 95% CI, 0.35 to 0.87). Further, kidney-replacement therapy was used in 24 patients (1.4%) in the amino acid cohort compared to 33 patients (1.9%) in the placebo cohort. In terms of safety, investigators did not observe any substantial differences between either cohort in other secondary outcomes or adverse events.
“The infusion of amino acids appeared to be safe and effective for the prevention of AKI in patients undergoing cardiac surgery,” the study authors wrote. “Moreover, the lower percentage of patients with stage 3 AKI in the amino acid group than in the placebo group implied an effect on AKI severity. These findings appear to be clinically and epidemiologically important because they may apply to more than two million patients who undergo heart surgery worldwide every year and because AKI is an independent risk factor for subsequent chronic kidney disease.”1
References
1. Landoni G, et al. A Randomized Trial of Intravenous Amino Acids for Kidney Protection. N Engl J Med 2024;391:687-698. DOI: 10.1056/NEJMoa2403769. Vol. 391 No. 8.
2. Intravenous Amino Acid Therapy for Kidney Protection in Cardiac Surgery. (PROTection). ClinicalTrials.gov ID. April 5, 2024. https://clinicaltrials.gov/study/NCT03709264
Investigational Pain Therapy Cebranopadol Succeeds in Second Phase III Clinical Trial
March 6th 2025Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a statistically significant and high level of pain reduction compared to placebo.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Xolair Outperforms Oral Immunotherapy in Landmark Phase III OUtMATCH Food Allergy Trial
March 3rd 2025Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food allergies in the Phase III OUtMATCH trial, suggesting the potential to facilitate the introduction of allergenic foods into patients' diets after treatment.
